$5.51
3.18% today
NYSE, Apr 01, 06:51 pm CET
ISIN
US04635X1028
Symbol
ATXS
Sector
Industry

Astria Therapeutics Stock price

$5.34
-1.10 17.08% 1M
-5.67 51.50% 6M
-3.60 40.27% YTD
-8.17 60.47% 1Y
-1.37 20.42% 3Y
-19.56 78.55% 5Y
-774.66 99.32% 10Y
NYSE, Closing price Mon, Mar 31 2025
-0.36 6.32%
ISIN
US04635X1028
Symbol
ATXS
Sector
Industry

Key metrics

Market capitalization $301.36m
Enterprise Value $73.90m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.35
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-111.56m
Free Cash Flow (TTM) Free Cash Flow $-81.54m
Cash position $328.13m
EPS (TTM) EPS $-1.69
P/E forward negative
Short interest 5.87%
Show more

Is Astria Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Astria Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Astria Therapeutics forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Astria Therapeutics forecast:

Buy
100%

Financial data from Astria Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 34 34
34% 34%
-
- Research and Development Expense 77 77
83% 83%
-
-112 -112
64% 64%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -112 -112
64% 64%
-
Net Profit -94 -94
29% 29%
-

In millions USD.

Don't miss a Thing! We will send you all news about Astria Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Astria Therapeutics Stock News

Neutral
Business Wire
21 days ago
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. “2025 promises to be an exciting year for Astria, and we are building on the momentum from...
Neutral
Business Wire
28 days ago
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 87,450 shares of Astria's common stock on March 3, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant ...
Neutral
Business Wire
about one month ago
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 9:50am ET in Boston, MA. A we...
More Astria Therapeutics News

Company Profile

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Head office United States
CEO Jill Milne
Employees 78
Founded 2008
Website www.astriatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today